Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications.
Vietor J, Gege C, Stiller T, Busch R, Schallmayer E, Kohlhof H, Höfner G, Pabel J, Marschner JA, Merk D. Vietor J, et al. Among authors: busch r. J Med Chem. 2023 May 11;66(9):6391-6402. doi: 10.1021/acs.jmedchem.3c00415. Epub 2023 Apr 26. J Med Chem. 2023. PMID: 37127285 Free PMC article.
Nurr1 Modulation Mediates Neuroprotective Effects of Statins.
Willems S, Marschner JA, Kilu W, Faudone G, Busch R, Duensing-Kropp S, Heering J, Merk D. Willems S, et al. Among authors: busch r. Adv Sci (Weinh). 2022 Jun;9(18):e2104640. doi: 10.1002/advs.202104640. Epub 2022 Apr 30. Adv Sci (Weinh). 2022. PMID: 35488520 Free PMC article.
Chemogenomics for NR1 nuclear hormone receptors.
Isigkeit L, Schallmayer E, Busch R, Brunello L, Menge A, Elson L, Müller S, Knapp S, Stolz A, Marschner JA, Merk D. Isigkeit L, et al. Among authors: busch r. Nat Commun. 2024 Jun 18;15(1):5201. doi: 10.1038/s41467-024-49493-6. Nat Commun. 2024. PMID: 38890295 Free PMC article.
Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism.
Willems S, Busch R, Nawa F, Ballarotto M, Lillich FF, Kasch T, López-García Ú, Marschner JA, Rüger LA, Renelt B, Ohrndorf J, Arifi S, Zaienne D, Proschak E, Pabel J, Merk D. Willems S, et al. Among authors: busch r. J Med Chem. 2024 Aug 8;67(15):13324-13348. doi: 10.1021/acs.jmedchem.4c01218. Epub 2024 Jul 30. J Med Chem. 2024. PMID: 39081058
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
Multidisciplinary lifestyle interventions for neurological disorders during the Silent phase (MINDS) study: a multi-omics randomized controlled trial protocol.
Taylor S, Sachdeva S, Darling S, Arrotta K, Gallagher L, Supan A, Shipta G, Perko J, Bar J, James J, Petschek I, Lioi A, Kundu S, Ellison L, Bekris LM, Willard B, Sangwan N, Mata I, Fernandez H, Katzan I, Conway D, Pillai J, Leverenz J, Busch RM, Floden D, Saper R, Barnard J, Machado A, Najm I, Punia V. Taylor S, et al. Among authors: busch rm. Neurol Res Pract. 2024 Aug 1;6(1):39. doi: 10.1186/s42466-024-00334-3. Neurol Res Pract. 2024. PMID: 39085927 Free PMC article.
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone.
DeFronzo RA, Auchus RJ, Bancos I, Blonde L, Busch RS, Buse JB, Findling JW, Fonseca VA, Frias JP, Hamidi O, Handelsman Y, Pratley RE, Rosenstock J, Tudor IC, Moraitis AG, Einhorn D. DeFronzo RA, et al. Among authors: busch rs. BMJ Open. 2024 Jul 16;14(7):e081121. doi: 10.1136/bmjopen-2023-081121. BMJ Open. 2024. PMID: 39013654 Free PMC article.
873 results